Medical groups associated with telehealth companies that have been warned by the FDA for marketing combination weight loss drugs may also be under scrutiny.[1] The article focuses on telehealth for prescribers.[1] Eli Lilly enforces measures against drug compounding.[1] These topics are part of broader reports in the field of pharmacy.[1] The FDA has warned telehealth companies about promoting uncontrolled weight-loss combination products.[1] Medical groups may face further scrutiny for this marketing.[1] The article summarizes the current reading on these developments and other pharmaceutical innovations.[1]